What is the latest price of Ensifentrine in 2025?

Ohtuvayre (Ensifentrine)-Ensefentrine/Ensifentrine inhalation suspension is a new inhaled drug that has received widespread attention in Europe and the United States in recent years. It is mainly used to treat chronic obstructive pulmonary disease (COPD), including clinical subtypes such as chronic bronchitis and emphysema. It is an innovative drug with a dual mechanism of action. By inhibiting phosphodiesterase type 3 (PDE3) and phosphodiesterase type 4 (PDE4) at the same time, it can not only rapidly dilate the bronchus, but also has anti-inflammatory properties. It has unique advantages in improving lung function, alleviating chronic airway inflammation, and improving patients' quality of life. Especially for patients with moderate to severe COPD who do not respond well to traditional single-mechanism treatments, exefentine may serve as a potential alternative or complementary option.

The current indications for ensefentin are mainly focused on long-term maintenance treatment of COPD, rather than emergency management of acute attacks. Clinically, its twice-daily inhalation administration method is simple and stable, which helps improve patients' treatment compliance and reduces dose deviations caused by complex inhaler operation. In addition, compared with traditional PDE4 inhibitors, exefentine has better gastrointestinal tolerance and is therefore more suitable for long-term maintenance use.

In terms of price, Ensefentin has not yet received marketing approval in mainland China, so its original research version cannot be purchased through conventional channels. However, according to data, the drug has been marketed in the United States and other countries under the trade name "OMJIRIA", with a specification of 3mg/2.5mL (each box contains 60 doses). Prices in overseas markets are relatively high, equivalent to more than 40,000 yuan in RMB. The final selling price may vary due to exchange rate fluctuations, regional taxes and other factors. At the same time, because there is no generic version of this drug yet, there is no price competition mechanism, and it is not included in any national medical insurance system. As a result, the current cost of medication still puts a certain amount of economic pressure on ordinary patients.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html